After a patient with vulvovaginal candidiasis was treated with fluconazole but tested negative for Candida albicans and symptoms persisted and recurred, what are the next diagnostic and therapeutic steps?

Next Steps for Persistent VVC Symptoms After Negative Testing

When symptoms persist or recur despite negative testing for Candida albicans after fluconazole treatment, you must obtain vaginal culture with antifungal susceptibility testing to identify non-albicans species or azole-resistant strains, as these are the most common causes of treatment failure. 1

Immediate Diagnostic Steps

Obtain Comprehensive Microbiological Testing

• Perform vaginal culture for Candida species - this is the gold standard and essential for identifying non-albicans species that may be fluconazole-resistant 1
• Request antifungal susceptibility testing on any isolated Candida species, as azole resistance can develop even in C. albicans 1, 2
• Consider PCR testing if available, which has superior sensitivity (90.9%) and specificity (94.1%) compared to microscopy 1

Key Clinical Pitfall

Negative microscopy or rapid testing does not rule out VVC - approximately 50% of infected patients have negative microscopy, and culture takes 48-72 hours but is necessary for accurate species identification 1

Therapeutic Algorithm Based on Culture Results

If Candida glabrata is Identified

C. glabrata is frequently dose-dependent susceptible or resistant to fluconazole 1, 3

First-line treatment options:

• Intravaginal boric acid 600 mg daily for 14 days (gelatin capsule) - this is the preferred alternative for azole-unresponsive C. glabrata 1
• Nystatin intravaginal suppositories 100,000 units daily for 14 days 1
• Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream daily for 14 days 1

If Candida krusei is Identified

C. krusei has intrinsic resistance to fluconazole both in vitro and clinically 4

• Vaginal boric acid remains the treatment of choice for C. krusei vaginitis 4
• Susceptibility testing often shows resistance to multiple azoles including miconazole and ketoconazole 4
• Itraconazole may show in vitro activity but frequently fails clinically 4

If Fluconazole-Resistant C. albicans is Identified

This is increasingly recognized as a cause of recurrent VVC 2

Treatment options:

• Consider newer oral agents: ibrexafungerp (FDA-approved 2021, first oral non-azole for VVC) or oteseconazole (approved for recurrent VVC) 5, 6
• Ibrexafungerp achieves vaginal tissue concentrations 9-fold higher than plasma and has superior cure rates at day 25 compared to fluconazole 5
• Alternative: intravaginal boric acid 600 mg daily for 14 days 1

If Culture Remains Negative But Symptoms Persist

• Reconsider the diagnosis - less than half of patients treated for VVC actually have objective evidence of infection 1
• Evaluate for alternative diagnoses: bacterial vaginosis, cytolytic vaginosis, vulvar dermatoses, contact dermatitis, or other non-infectious causes 1
• Consider referral to a vaginitis specialist for comprehensive evaluation 7, 3

If This Represents Recurrent VVC (≥3 Episodes/Year)

Induction Phase

• Provide 10-14 days of induction therapy with a topical agent or oral fluconazole (if susceptible) 1

Maintenance Phase

• Fluconazole 150 mg weekly for 6 months is the guideline-recommended maintenance regimen 1
• However, infection recurs in up to 50% of women after cessation of this regimen 7
• Ibrexafungerp received FDA approval in December 2022 for once-monthly dosing to decrease RVVC incidence, showing 65.4% resolution through week 24 versus 53.1% with placebo 5

Critical Evidence Considerations

Vaginal Relapse vs. Reinfection

• Studies demonstrate that 77% (17/22) of recurrent episodes are caused by the same strain (vaginal relapse), not reinfection 8
• This supports the need for more prolonged initial therapy to achieve eradication 8

Quality of Life Impact

• RVVC significantly impacts both physical and psychological well-being and poses substantial financial burden 7, 3
• Patient education and adherence to therapy regimens are crucial for successful treatment 3

When to Consider Novel Agents

Ibrexafungerp or oteseconazole should be considered for:

• Azole allergy 5
• Non-albicans species 5
• Azole-resistant C. albicans 5
• Drug interactions with azoles (statins, tricyclics) 5
• Recurrent VVC requiring long-term maintenance 5, 6